-
CSR Summary Not Yet Available
-
NCT01646021
-
Primary Citation
-
Data Specification Not Yet Available
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameIbrutinibProduct NameIMBRUVICA®Therapeutic AreaCancers and Other NeoplasmsEnrollment280% Female25.7%% White87.0%
Product ClassKinase InhibitorsSponsor Protocol NumberPCI-32765MCL3001Data PartnerJohnson & JohnsonCondition StudiedLymphoma, Mantle Cell/Small LymphocyticMean/Median Age (Years)66.9
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available